BBLG

Bone Biologics Corp

BBLG, USA

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

https://www.bonebiologics.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BBLG
stock
BBLG

Today's SEC Filings - Latest 10-K, 10-Q, 8-K Forms Stock Titan

Read more →
BBLG
stock
BBLG

Aug Fed Impact: Is Pixelworks Inc. stock undervalued right now - Earnings Beat & Safe Entry Point Alerts baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$22.25

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.52

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-11.08 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.50 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.06

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.34% of the total shares of Bone Biologics Corp

1.

Fidelity Extended Market Index

(0.1534%)

since

2025/07/31

2.

Spartan Extended Market Index Pool F

(0.0865%)

since

2025/07/31

3.

Fidelity Total Market Index

(0.0365%)

since

2025/07/31

4.

Fidelity Series Total Market Index

(0.0348%)

since

2025/07/31

5.

Tower Research Capital LLC

(0.0111%)

since

2025/06/30

6.

CLEAR STREET LLC.

(0.0077%)

since

2025/06/30

7.

UBS Group AG

(0.0063%)

since

2025/06/30

8.

Bank of America Corp

(0.0002%)

since

2025/06/30

9.

Geode Capital Management, LLC

(0%)

since

2025/06/30

10.

SBI Securities Co Ltd

(0%)

since

2025/06/30

11.

Citigroup Inc

(0%)

since

2025/03/31

12.

HRT FINANCIAL LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.37

EPS Estimate

-7.92

EPS Difference

7.55

Surprise Percent

95.3283%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Strong Net-Net(7)
Quality
Low Quality Business(2.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.